Found 142 with Last Name = 'sabatino' and Initial = 'd' TargetEstrogen receptor [D538G](Homo sapiens (Human))
Valorisation-Recherche, Limited Partnership
US Patent
Valorisation-Recherche, Limited Partnership
US Patent
Affinity DataIC50: 6.08nMAssay Description:GHS-R1a radioreceptor assay using LLCPK-1 membranes overexpressing GSH-R1a and radioiodinated (1-28) rat ghrelin as tracer.More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibition of radiolabeled fibrinogen binding to activated human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibition of radiolabeled fibrinogen binding to activated human platelets.More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Inhibition of radiolabeled fibrinogen binding to activated human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Inhibition of radiolabeled fibrinogen binding to activated human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Inhibition of radiolabeled fibrinogen binding to activated human platelets.More data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:Inhibition of radiolabeled fibrinogen binding to activated human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:Inhibition of radiolabeled fibrinogen binding to activated human platelets.More data for this Ligand-Target Pair
Affinity DataIC50: 19nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:Inhibition of radiolabeled fibrinogen binding to activated human platelets.More data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:Inhibition of radiolabeled fibrinogen binding to activated human platelets.More data for this Ligand-Target Pair
Affinity DataIC50: 26nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 27nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 28nMAssay Description:Inhibition of radiolabeled fibrinogen binding to activated human platelets.More data for this Ligand-Target Pair
Affinity DataIC50: 31nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 32nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 32nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 47nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 53nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 64nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 64nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 68nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 72nMAssay Description:Inhibition of radiolabeled fibrinogen binding to activated human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 72nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 78nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 82nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 96nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 97nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 110nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 129nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 130nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 210nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 260nMAssay Description:Inhibition of radiolabeled fibrinogen binding to activated human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 470nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
TargetEstrogen receptor [D538G](Homo sapiens (Human))
Valorisation-Recherche, Limited Partnership
US Patent
Valorisation-Recherche, Limited Partnership
US Patent
Affinity DataIC50: 568nMAssay Description:GHS-R1a radioreceptor assay using LLCPK-1 membranes overexpressing GSH-R1a and radioiodinated (1-28) rat ghrelin as tracer.More data for this Ligand-Target Pair
Affinity DataIC50: 630nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 720nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 770nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 1.06E+3nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
TargetPlatelet glycoprotein 4(Rattus norvegicus)
Valorisation-Recherche, Limited Partnership
US Patent
Valorisation-Recherche, Limited Partnership
US Patent
Affinity DataIC50: 1.34E+3nMpH: 7.3Assay Description:Competition experiments were performed by incubating 50 μg of LLC-PK1 membranes expressing human GHS-R1a with 15 fmol of 125I-Ghrelin and increa...More data for this Ligand-Target Pair
Affinity DataIC50: 1.37E+3nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
TargetPlatelet glycoprotein 4(Rattus norvegicus)
Valorisation-Recherche, Limited Partnership
US Patent
Valorisation-Recherche, Limited Partnership
US Patent
Affinity DataIC50: 1.80E+3nMpH: 7.3Assay Description:Competition experiments were performed by incubating 50 μg of LLC-PK1 membranes expressing human GHS-R1a with 15 fmol of 125I-Ghrelin and increa...More data for this Ligand-Target Pair
Affinity DataIC50: 2.30E+3nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
TargetPlatelet glycoprotein 4(Rattus norvegicus)
Valorisation-Recherche, Limited Partnership
US Patent
Valorisation-Recherche, Limited Partnership
US Patent
Affinity DataIC50: 2.89E+3nMpH: 7.3Assay Description:Competition experiments were performed by incubating 50 μg of LLC-PK1 membranes expressing human GHS-R1a with 15 fmol of 125I-Ghrelin and increa...More data for this Ligand-Target Pair
TargetPlatelet glycoprotein 4(Rattus norvegicus)
Valorisation-Recherche, Limited Partnership
US Patent
Valorisation-Recherche, Limited Partnership
US Patent
Affinity DataIC50: 2.95E+3nMpH: 7.3Assay Description:Competition experiments were performed by incubating 50 μg of LLC-PK1 membranes expressing human GHS-R1a with 15 fmol of 125I-Ghrelin and increa...More data for this Ligand-Target Pair
TargetPlatelet glycoprotein 4(Rattus norvegicus)
Valorisation-Recherche, Limited Partnership
US Patent
Valorisation-Recherche, Limited Partnership
US Patent
Affinity DataIC50: 2.97E+3nMpH: 7.3Assay Description:Competition experiments were performed by incubating 50 μg of LLC-PK1 membranes expressing human GHS-R1a with 15 fmol of 125I-Ghrelin and increa...More data for this Ligand-Target Pair
TargetPlatelet glycoprotein 4(Rattus norvegicus)
Valorisation-Recherche, Limited Partnership
US Patent
Valorisation-Recherche, Limited Partnership
US Patent
Affinity DataIC50: 3.33E+3nMpH: 7.3Assay Description:Competition experiments were performed by incubating 50 μg of LLC-PK1 membranes expressing human GHS-R1a with 15 fmol of 125I-Ghrelin and increa...More data for this Ligand-Target Pair
Affinity DataIC50: 3.41E+3nMAssay Description:Ability of the compound to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 3.50E+3nMAssay Description:Inhibition of HUVEC adhesion to fibrinogen-coated platesMore data for this Ligand-Target Pair
TargetPlatelet glycoprotein 4(Rattus norvegicus)
Valorisation-Recherche, Limited Partnership
US Patent
Valorisation-Recherche, Limited Partnership
US Patent
Affinity DataIC50: 3.68E+3nMpH: 7.3Assay Description:Competition experiments were performed by incubating 50 μg of LLC-PK1 membranes expressing human GHS-R1a with 15 fmol of 125I-Ghrelin and increa...More data for this Ligand-Target Pair
